A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease
ID: NCT03384966
Our intelligence engine has synthesized this trial record to answer your most important questions in clear, simple terms:
The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly. Another goal is to know how fast and for how long selatogrel (ACT-246475) works and if there is a difference if the drug is injected in the thigh or in the belly. This study will also help to find out more about the safety of this new drug.
Read Full Scientific Objectives & Methods
To investigate the pharmacodynamic (PD) and pharmacokinetic (PK) properties of selatogrel in patients with atherosclerotic disease, the present study will be conducted in patients with chronic coronary syndromes (CCS). Assessment in a population of patients with CCS allows better control and stability of concomitant treatments, and therefore more accurate characterization of the pharmacodynamic and pharmacokinetic profiles of selatogrel in the presence of background antiplatelet therapies. The study will have 3 periods: a screening period of up to 21 days prior to randomization, a treatment period of 2 days from randomization (Day 1) to 24 hours post dose (Day 2), and a follow-up period from Day 3 to the safety follow-up telephone call 28 to 35 days after single administration of study drug (End-of-Study).
Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.
Matching placebo for subcutaneous administration.
Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
Treatment Arms Description
Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
- Signed informed consent prior to any study-mandated procedure.
- Male and female subjects aged from 18-85 years, inclusive.
- For women of childbearing potential: Negative urine pregnancy test at Visit 1 and at Visit 2 before randomization.
- Stable Coronary artery disease (CAD) defined by the presence of any of the following conditions:
- History of CAD with coronary artery stenosis on coronary angiogram ≥50%.
- Previously documented myocardial infarction occurring more than 3 months prior to randomization.
- Antiplatelet background therapy stable for at least 1 month prior to randomization.
- Body weight ≥ 40.0 kg (88.2 lbs).
- Acute coronary syndrome, percutaneous coronary intervention or any intervention for peripheral artery disease within 3 months prior to randomization.
- Acute ischemic stroke or transient ischemic attack (TIA) within 3 months prior to randomization.
- Active internal bleeding, or medical history of recent (\< 1 month) bleeding disorders or conditions associated with high risk of bleeding (e.g., clotting disturbances, gastrointestinal bleed, hemoptysis).
- Hemoglobin ≤ 10 g/dL at screening.
- Loss of at least 250 mL of blood within 3 months of screening.
- Use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior to screening (Visit 1).
- Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Willebrand disease).
- Pregnant or breastfeeding women.
Primary Outcome Measures
- Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation — Time Frame: From 15 minutes after administration of the subcutaneous injection up to 24 hours
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a "responder".
View Secondary Outcome Measures (3)
- Maximum Selatogrel Plasma Concentration (Cmax) — Time Frame: Pre-dose, and from 15 minutes after administration of the subcutaneous injection up to 24 hours
The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection. The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.
- Time to Reach Maximum Selatogrel Plasma Concentration (Tmax) — Time Frame: Pre-dose, and from 15 minutes after administration of the subcutaneous injection up to 24 hours
Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax).
- Area Under the Plasma Concentration-time Curve of Selatogrel From Time Zero to 24 Hour Time Point (AUC0-24) — Time Frame: Pre-dose, and from 15 minutes after administration of the subcutaneous injection up to 24 hours post-dose
The area under the plasma concentration-time curve is the integral of the concentration-time curve after subcutaneous injection of selatogrel. The plasma pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.
This trial is recruiting at 20 study facilities worldwide. Click below to see if there is a clinic or hospital in your area:
Show All 20 Facilities & Contact Sites
Want to apply or inquire about joining this study? Fill out this simple questionnaire, and our assistant will instantly generate a professional email draft you can copy and send to the central contact coordinator listed above!
- Storey RF, Gurbel PA, Ten Berg J, Bernaud C, Dangas GD, Frenoux JM, Gorog DA, Hmissi A, Kunadian V, James SK, Tanguay JF, Tran H, Trenk D, Ufer M, Van der Harst P, Van't Hof AWJ, Angiolillo DJ. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J. 2020 Sep 1;41(33):3132-3140. doi: 10.1093/eurheartj/ehz807.PubMed ↗
View Official Medical/Scientific Title
A Multi-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Pharmacodynamics, Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Injection of ACT-246475 in Adults With Stable Coronary Artery Disease